These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 4090451)

  • 1. [Clinical study of the effect of the administration of cathergen preparation in patients with chronic hepatic lesions].
    Maleev A; Tsvetkova V; Krŭstev Z; Kostova N; Lukanov L
    Vutr Boles; 1985; 24(5):39-43. PubMed ID: 4090451
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new therapy of hepatic insufficiency. Experiments with (+)-3--cyanidanol. Its importance in the treatment of alcoholic hepatitis].
    Traissac FJ; Borg R
    Minerva Dietol Gastroenterol; 1977; 23(3):237-42. PubMed ID: 372845
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Catergen [(+)cyanidanol-3] on some haemostatic parameters in chronic liver diseases.
    Pfliegler G; Boda Z; Dalmi L; Weisz G; Misz M; Beck P
    Ther Hung; 1984; 32(1):19-25. PubMed ID: 6571189
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of chronic diseases of the liver with catergen].
    Loginov AS; Dzhalalov KD; Blok IuE; Bendikov EA; Ausheva LKh
    Ter Arkh; 1986; 58(2):73-6. PubMed ID: 3704945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Enzymologic evaluation of the effectiveness of the hepatotropic drug catergen in chronic liver diseases].
    Tamarkina AD; Neverov IV; Turitsyna IG; Dement'eva ES; Krylova NI
    Sov Med; 1985; (12):26-30. PubMed ID: 4095626
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of carsil and legalon in treating chronic liver diseases].
    Brailski Kh; Chernev K; Etŭrska M; Donov M; Velev G
    Vutr Boles; 1986; 25(3):43-9. PubMed ID: 3765578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of therapy in chronic liver diseases. Double-blind study with cianidanol].
    Machalke K; Müller B
    Fortschr Med; 1982 Apr; 100(14):665-7. PubMed ID: 6123478
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of ornithine carbamoyltransferase in the treatment of liver diseases].
    Caruso N; De Jacobis M; Roccato M; Sequino A; Sgoifo B; Tinello M
    Clin Ter; 1984 Jul; 110(1):37-44. PubMed ID: 6237844
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of chronic hepatitis patients with catergen].
    Karkishchenko NN; Okorokov AN; Fedorov NE; Laktionova AA; Sidorenko LF
    Ter Arkh; 1986; 58(2):76-9. PubMed ID: 3704946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience with silymarin in the treatment of chronic liver disease(author's transl)].
    Reutter FW; Haase W
    Schweiz Rundsch Med Prax; 1975 Sep; 64(36):1145-51. PubMed ID: 1099576
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
    Halmy L; Dávid K; Nagy I; Stotz G; Kelemen JT
    Acta Physiol Hung; 1984; 64(3-4):461-70. PubMed ID: 6152370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical investigation of silymarin in chronic liver diseases (author's transl)].
    Realini S; Gonvers JJ; Hofstetter JR
    Schweiz Rundsch Med Prax; 1975 May; 64(19):595-8. PubMed ID: 51497
    [No Abstract]   [Full Text] [Related]  

  • 13. [Thiomesterone and liver function].
    Pickert H
    Med Klin; 1968 Aug; 63(31):1222-6. PubMed ID: 5719699
    [No Abstract]   [Full Text] [Related]  

  • 14. [The anti-steatosic effect of sulfo-adenosylmethionine (SAMe) in various forms of chronic hepatopathy. Multicentric research].
    Mazzanti R; Arcangeli A; Salvadori G; Smorlesi C; Di Perri T; Auteri A; Boggiano CA; Pippi L; Toti M; Boncompagni P; Angioli D; Caremani M; Magnolfi F; Camarri E; Motta R; Forconi A; Candidi Tommasi A; Lomi M; Soldi A
    Minerva Med; 1978 Oct; 69(48):3283-92. PubMed ID: 724140
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.
    Abonyi M; Kisfaludy S; Szalay F
    Acta Physiol Hung; 1984; 64(3-4):455-60. PubMed ID: 6397971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatoprotective drugs. Clinical results of the use of a sulfhydryl-methylating preparation].
    Rapino P; Marulli R; Rapex G; Della Lunga S; Sabatino P
    Minerva Med; 1982 Oct; 73(40):2853-60. PubMed ID: 7133498
    [No Abstract]   [Full Text] [Related]  

  • 17. [Glucocorticoids in chronic liver diseases].
    Maier KP; Talke H; Gerok W
    Dtsch Med Wochenschr; 1975 Mar; 100(11):560-3. PubMed ID: 1116441
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical experimentation with Aïcamine in hepatic insufficiency].
    Négret JP
    Bord Med; 1972 Apr; 5(8):973-6. PubMed ID: 5053280
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of (+)-cyanidanol-3 on chronic liver injury.
    Kovách G; Salamon F
    Acta Physiol Hung; 1984; 64(3-4):443-8. PubMed ID: 6152368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What is certain in the therapy of hepatocellular diseases with cyanidanol?].
    Schomerus H
    Internist (Berl); 1983 Dec; 24(12):684-9. PubMed ID: 6363332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.